143 related articles for article (PubMed ID: 29423936)
1. Population pharmacokinetics of enoxaparin in early stage of paediatric liver transplantation.
Oualha M; Chardot C; Debray D; Lesage F; Harroche A; Renolleau S; Treluyer JM; Urien S
Br J Clin Pharmacol; 2018 Jun; 84(6):1206-1214. PubMed ID: 29423936
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of Enoxaparin After Renal Transplantation in Pediatric Patients.
Damamme A; Urien S; Borgel D; Lasne D; Krug P; Krid S; Charbit M; Salomon R; Treluyer JM; Boyer O
J Clin Pharmacol; 2018 Dec; 58(12):1597-1603. PubMed ID: 30256422
[TBL] [Abstract][Full Text] [Related]
3. Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.
Feng Y; Green B; Duffull SB; Kane-Gill SL; Bobek MB; Bies RR
Br J Clin Pharmacol; 2006 Aug; 62(2):165-76. PubMed ID: 16842391
[TBL] [Abstract][Full Text] [Related]
4. Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD.
Israel EN; Thomas CA; Mastropietro CW
Cardiol Young; 2018 May; 28(5):715-718. PubMed ID: 29490713
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Enoxaparin in Pediatric Patients.
Moffett BS; Lee-Kim Y; Galati M; Mahoney D; Shah MD; Teruya J; Yee D
Ann Pharmacother; 2018 Feb; 52(2):140-146. PubMed ID: 28962537
[TBL] [Abstract][Full Text] [Related]
6. Low-molecular-weight heparin in thrombotic disease in children and adolescents.
Punzalan RC; Hillery CA; Montgomery RR; Scott CA; Gill JC
J Pediatr Hematol Oncol; 2000; 22(2):137-42. PubMed ID: 10779027
[TBL] [Abstract][Full Text] [Related]
7. Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment.
Hulot JS; Vantelon C; Urien S; Bouzamondo A; Mahé I; Ankri A; Montalescot G; Lechat P
Ther Drug Monit; 2004 Jun; 26(3):305-10. PubMed ID: 15167633
[TBL] [Abstract][Full Text] [Related]
8. Retrospective comparison of two enoxaparin dosing and monitoring protocols at a pediatric hospital.
Wolsey A; Wilcox RA; Olson JA; Boehme S; Anderson CR
Am J Health Syst Pharm; 2019 May; 76(11):815-819. PubMed ID: 31361813
[TBL] [Abstract][Full Text] [Related]
9. Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital.
Andrade-Campos MM; Montes-Limón AE; Fernandez-Mosteirin N; Salvador-Osuna C; Torres M; Lucia-Cuesta JF; Rubio-Felix D
Blood Coagul Fibrinolysis; 2013 Mar; 24(2):194-8. PubMed ID: 23358201
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study.
Trame MN; Mitchell L; Krümpel A; Male C; Hempel G; Nowak-Göttl U
J Thromb Haemost; 2010 Sep; 8(9):1950-8. PubMed ID: 20586920
[TBL] [Abstract][Full Text] [Related]
11. Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety.
Kane-Gill SL; Feng Y; Bobek MB; Bies RR; Pruchnicki MC; Dasta JF
J Clin Pharm Ther; 2005 Jun; 30(3):207-13. PubMed ID: 15896237
[TBL] [Abstract][Full Text] [Related]
12. Leveraging physiological data from literature into a pharmacokinetic model to support informative clinical study design in pregnant women.
van Hasselt JG; Green B; Morrish GA
Pharm Res; 2012 Jun; 29(6):1609-17. PubMed ID: 22246291
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
Sofjan AK; Iuppa JA; Bain KB; Deal EN; Witt CA; Hachem RR; Yusen RD
Ann Pharmacother; 2016 Oct; 50(10):824-31. PubMed ID: 27363845
[TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin.
Gulati A; Faed JM; Isbister GK; Duffull SB
Pharm Res; 2012 Jan; 29(1):225-35. PubMed ID: 21822767
[TBL] [Abstract][Full Text] [Related]
15. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.
Barrett YC; Wang J; Song Y; Pursley J; Wastall P; Wright R; Lacreta F; Frost C
Thromb Haemost; 2012 May; 107(5):916-24. PubMed ID: 22398784
[TBL] [Abstract][Full Text] [Related]
16. Arterial line versus venous line administration of low molecular weight heparin, enoxaparin for prevention of thrombosis in the extracorporeal blood circuit of patients on haemodialysis or haemodiafiltration: A randomized cross-over trial.
Kurtkoti J; Bose B; Hiremagalur B; Sun J; Cochrane T
Nephrology (Carlton); 2016 Aug; 21(8):663-8. PubMed ID: 26609786
[TBL] [Abstract][Full Text] [Related]
17. Enoxaparin Population Pharmacokinetics in the First Year of Life.
Moffett BS; Galati M; Mahoney D; Lee-Kim Y; Teruya J; Shah MD; Yee DL
Ther Drug Monit; 2017 Dec; 39(6):632-639. PubMed ID: 28937536
[TBL] [Abstract][Full Text] [Related]
18. Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin.
Ramos-Esquivel A; Salazar-Sánchez L
Thromb Res; 2013 Oct; 132(4):433-6. PubMed ID: 24050826
[TBL] [Abstract][Full Text] [Related]
19. Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin.
Maurice-Dror C; Litvak M; Keren-Politansky A; Ackerman S; Haim N; Nadir Y
J Thromb Thrombolysis; 2020 Jul; 50(1):112-122. PubMed ID: 32377957
[TBL] [Abstract][Full Text] [Related]
20. Enoxaparin: pharmacokinetics and treatment schedule for cats.
Mischke R; Schönig J; Döderlein E; Wolken S; Böhm C; Kietzmann M
Vet J; 2014 Jun; 200(3):375-81. PubMed ID: 24810867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
